NBIX — Neurocrine Biosciences, Inc.
$142.70-0.41%
Last close: · regular session
Last 60 sessions
NBIX closed at $142.70 (-0.41%) on Oct 23, 2026. Float: 97.4M shares. Latest SEC filing: SCHEDULE 13G/A on Oct 15, 2026.
Opening the full analysis uses 1 of your 3 free tickers today.
Chart, dilution, float and news for NBIX in the TickerWise workspace.
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, a VMAT2 inhibitor for the treatment of tardive dyskinesia. The company's commercial products include ONGENTYS, a catechol-O-methyltransferase inhibitor used as an adjunct therapy to levodopa/DOPA decarboxylase inhibitors for patients with Parkinson's disease; ORILISSA for the management of moderate to severe endometriosis pain in women; and ORIAHNN, a non-surgical oral medication option for the management of heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women. Its product candidates in clinical development include NBI-921352 for treating pediatric patients, as well as adult focal epilepsy indications; and NBI-827104 to treat rare pediatric epilepsy and essential tremor. The company's products in clinical development also comprise NBI-1065845 for the treatment of major depressive disorder; NBI-1065846 for treating anhedonia in major depressive disorder; and NBI-118568 for the treatment of schizophrenia. It has license and collaboration agreements with Heptares Therapeutics Limited; Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. Neurocrine Biosciences, Inc. was incorporated in 1992 and is headquartered in San Diego, California.
Company profile
- Sector: Healthcare
- Industry: Drug Manufacturers - Specialty & Generic
- Country: US
- Exchange: NASDAQ
- Employees: 1,800
- Website: https://www.neurocrine.com
Latest SEC filings for NBIX
Latest NBIX news
- Where Will Neurocrine Biosciences Be in 5 Years? Read article
- Why Neurocrine Biosciences (NBIX) is a Top Value Stock for the Long-Term Read article
- NBIX vs. SDZNY: Which Stock Should Value Investors Buy Now? Read article
- Why Neurocrine Biosciences (NBIX) is a Top Growth Stock for the Long-Term Read article
- Neurocrine Biosciences Announces Conference Call and Webcast of Third Quarter 2026 Financial Results Read article
- Neurocrine Biosciences to Present Research Advancing Understanding of Prader-Willi Syndrome and Real-World Experience with VYKAT® XR (diazoxide choline) at Foundation for Prader-Willi Research Symposium & Family Conference Read article
- Neurocrine Biosciences Appoints Eiry W. Roberts, M.D. Read article
Related companies
Opening the full analysis uses 1 of your 3 free tickers today.
Educational tool only — not investment advice.